Artiva Biotherapeutics (NASDAQ:ARTV) Earns Buy Rating from Needham & Company LLC

Artiva Biotherapeutics (NASDAQ:ARTV)‘s stock had its “buy” rating reaffirmed by stock analysts at Needham & Company LLC in a research report issued on Friday,Benzinga reports. They presently have a $18.00 price objective on the stock. Needham & Company LLC’s price target would indicate a potential upside of 199.50% from the company’s current price.

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Artiva Biotherapeutics in a research note on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $18.25.

Artiva Biotherapeutics Price Performance

ARTV opened at $6.01 on Friday. The business’s 50-day moving average price is $2.91 and its two-hundred day moving average price is $2.44. Artiva Biotherapeutics has a 1 year low of $1.47 and a 1 year high of $15.49.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings data on Wednesday, August 6th. The company reported ($0.87) earnings per share for the quarter, missing the consensus estimate of ($0.84) by ($0.03). Equities analysts anticipate that Artiva Biotherapeutics will post -4.95 EPS for the current year.

Insiders Place Their Bets

In other Artiva Biotherapeutics news, CEO Fred Aslan sold 25,500 shares of the business’s stock in a transaction that occurred on Friday, October 17th. The stock was sold at an average price of $6.00, for a total transaction of $153,000.00. Following the transaction, the chief executive officer owned 356,721 shares of the company’s stock, valued at $2,140,326. The trade was a 6.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 21.40% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Artiva Biotherapeutics

Institutional investors have recently added to or reduced their stakes in the company. Ground Swell Capital LLC bought a new stake in Artiva Biotherapeutics during the second quarter worth $38,000. Y Intercept Hong Kong Ltd acquired a new position in shares of Artiva Biotherapeutics during the 2nd quarter worth about $48,000. Bridgeway Capital Management LLC bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $53,000. Qube Research & Technologies Ltd bought a new stake in shares of Artiva Biotherapeutics in the 2nd quarter valued at about $58,000. Finally, Jane Street Group LLC acquired a new stake in Artiva Biotherapeutics in the 2nd quarter valued at about $67,000.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company’s lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.